Contents

Current Cancer Drug Targets, Volume 4 - Number 6

Nerve Growth Factor Receptors and Signaling in Breast Cancer

, 4(6): 463 - 470

Laurent Dolle, Eric Adriaenssens, Ikram El Yazidi-Belkoura, Xuefen Le Bourhis, Victor Nurcombe and Hubert Hondermarck


DOI: 10.2174/1568009043332853




Heparin Affin Regulatory Peptide: A New Target for Tumour Therapy?

, 4(6): 471 - 482

E. Papadimitriou, A. Polykratis, M. Hatziapostolou, A. Parthymou, C. Polytarchou and C. Mikelis


DOI: 10.2174/1568009043332835




Estrogen Receptors as Targets for Drug Development for Breast Cancer, Osteoporosis and Cardiovascular Diseases

, 4(6): 483 - 499

Thresia Thomas, Michael A. Gallo and T. J. Thomas


DOI: 10.2174/1568009043332880




Two-Domain Vascular Disruptive Agents in Cancer Therapy

, 4(6): 501 - 509

Stanislaw Szala


DOI: 10.2174/1568009043332826




The Relationship Between Oncogene Expression and Clinical Outcome in Endometrial Carcinoma

, 4(6): 511 - 520

Noriyuki Takai, Tami Ueda, Masakazu Nishida, Kaei Nasu and Isao Miyakawa


DOI: 10.2174/1568009043332871




TSC-22 (TGF-β Stimulated Clone-22): A Novel Molecular Target for Differentiation-Inducing Therapy in Salivary Gland Cancer

, 4(6): 521 - 529

H. Kawamata, T. Fujimori and Y. Imai


DOI: 10.2174/1568009043332844




Mammaglobin-Based Strategies for Treatment of Breast Cancer

, 4(6): 531 - 542

Peter S. Goedegebuure, Mark A. Watson, Carsten T. Viehl and Timothy P. Fleming


DOI: 10.2174/1568009043332862




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science